nodes	percent_of_prediction	percent_of_DWPC	metapath
Lithium—GSK3A—FOXM1 transcription factor network—CENPB—systemic scleroderma	0.0482	0.145	CbGpPWpGaD
Lithium—GSK3B—Integrin-linked kinase signaling—GIT2—systemic scleroderma	0.0217	0.0655	CbGpPWpGaD
Lithium—GSK3B—connective tissue—systemic scleroderma	0.0187	0.104	CbGeAlD
Lithium—IMPA2—skin of body—systemic scleroderma	0.0172	0.0956	CbGeAlD
Lithium—GSK3B—smooth muscle tissue—systemic scleroderma	0.0171	0.095	CbGeAlD
Lithium—GSK3A—connective tissue—systemic scleroderma	0.0162	0.0903	CbGeAlD
Lithium—GSK3A—smooth muscle tissue—systemic scleroderma	0.0148	0.0826	CbGeAlD
Lithium—IMPA1—Integrated Breast Cancer Pathway—SMAD7—systemic scleroderma	0.0139	0.0419	CbGpPWpGaD
Lithium—IMPA2—digestive system—systemic scleroderma	0.0137	0.0765	CbGeAlD
Lithium—GSK3B—digestive system—systemic scleroderma	0.0135	0.075	CbGeAlD
Lithium—IMPA2—tendon—systemic scleroderma	0.0131	0.0728	CbGeAlD
Lithium—GSK3A—FOXM1 transcription factor network—CENPA—systemic scleroderma	0.0127	0.0383	CbGpPWpGaD
Lithium—GSK3B—Aurora A signaling—CENPA—systemic scleroderma	0.012	0.0361	CbGpPWpGaD
Lithium—GSK3A—digestive system—systemic scleroderma	0.0117	0.0652	CbGeAlD
Lithium—IMPA2—lung—systemic scleroderma	0.0115	0.0639	CbGeAlD
Lithium—GSK3B—lung—systemic scleroderma	0.0113	0.0626	CbGeAlD
Lithium—GSK3A—tendon—systemic scleroderma	0.0112	0.0621	CbGeAlD
Lithium—GSK3B—BMP receptor signaling—SMAD7—systemic scleroderma	0.0107	0.0324	CbGpPWpGaD
Lithium—GSK3A—T-Cell Receptor and Co-stimulatory Signaling—CTLA4—systemic scleroderma	0.00981	0.0296	CbGpPWpGaD
Lithium—GSK3A—lung—systemic scleroderma	0.00979	0.0545	CbGeAlD
Lithium—GSK3B—T-Cell Receptor and Co-stimulatory Signaling—CTLA4—systemic scleroderma	0.00725	0.0219	CbGpPWpGaD
Lithium—GSK3B—Hair Follicle Development: Induction (Part 1 of 3)—CTGF—systemic scleroderma	0.00594	0.0179	CbGpPWpGaD
Lithium—GSK3B—Semaphorin interactions—RHOB—systemic scleroderma	0.00572	0.0173	CbGpPWpGaD
Lithium—GSK3B—Melatonin metabolism and effects—EDN1—systemic scleroderma	0.0057	0.0172	CbGpPWpGaD
Lithium—GSK3A—Integrated Breast Cancer Pathway—SMAD7—systemic scleroderma	0.00522	0.0158	CbGpPWpGaD
Lithium—GSK3A—GAB1 signalosome—CSK—systemic scleroderma	0.00504	0.0152	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	0.00485	0.0147	CbGpPWpGaD
Lithium—IMPA1—Integrated Breast Cancer Pathway—MMP1—systemic scleroderma	0.0046	0.0139	CbGpPWpGaD
Lithium—GSK3A—B Cell Receptor Signaling Pathway—BLK—systemic scleroderma	0.00456	0.0138	CbGpPWpGaD
Lithium—GSK3B—Androgen receptor signaling pathway—RHOB—systemic scleroderma	0.00456	0.0138	CbGpPWpGaD
Lithium—GSK3B—Neural Crest Differentiation—RHOB—systemic scleroderma	0.00412	0.0124	CbGpPWpGaD
Lithium—GSK3B—Glucocorticoid receptor regulatory network—IL13—systemic scleroderma	0.00392	0.0118	CbGpPWpGaD
Lithium—GSK3B—Validated transcriptional targets of deltaNp63 isoforms—IL1A—systemic scleroderma	0.00385	0.0116	CbGpPWpGaD
Lithium—GSK3A—FOXM1 transcription factor network—MMP2—systemic scleroderma	0.00373	0.0113	CbGpPWpGaD
Lithium—GSK3B—GAB1 signalosome—CSK—systemic scleroderma	0.00372	0.0112	CbGpPWpGaD
Lithium—GSK3B—Senescence and Autophagy in Cancer—IRF5—systemic scleroderma	0.00358	0.0108	CbGpPWpGaD
Lithium—GSK3B—Circadian rythm related genes—TOP1—systemic scleroderma	0.00344	0.0104	CbGpPWpGaD
Lithium—GSK3B—B Cell Receptor Signaling Pathway—BLK—systemic scleroderma	0.00337	0.0102	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR—CSK—systemic scleroderma	0.00321	0.00969	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR in Cancer—CSK—systemic scleroderma	0.00318	0.00961	CbGpPWpGaD
Lithium—GSK3B—TWEAK Signaling Pathway—CCL2—systemic scleroderma	0.0029	0.00875	CbGpPWpGaD
Lithium—GSK3A—B Cell Activation—BLK—systemic scleroderma	0.00261	0.00787	CbGpPWpGaD
Lithium—GSK3B—Focal Adhesion—RHOB—systemic scleroderma	0.00248	0.0075	CbGpPWpGaD
Lithium—GSK3B—MicroRNAs in cardiomyocyte hypertrophy—EDN1—systemic scleroderma	0.00244	0.00735	CbGpPWpGaD
Lithium—GSK3A—Unfolded Protein Response (UPR)—CCL2—systemic scleroderma	0.00239	0.00722	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—CSK—systemic scleroderma	0.00237	0.00716	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—CSK—systemic scleroderma	0.00235	0.0071	CbGpPWpGaD
Lithium—GSK3B—Focal Adhesion—COL1A2—systemic scleroderma	0.00234	0.00707	CbGpPWpGaD
Lithium—GSK3A—Leptin signaling pathway—NOS3—systemic scleroderma	0.0022	0.00664	CbGpPWpGaD
Lithium—GSK3B—Focal Adhesion—ITGAM—systemic scleroderma	0.00213	0.00642	CbGpPWpGaD
Lithium—GSK3B—Glucocorticoid receptor regulatory network—MMP1—systemic scleroderma	0.00209	0.0063	CbGpPWpGaD
Lithium—GSK3B—TWEAK Signaling Pathway—MMP9—systemic scleroderma	0.00207	0.00626	CbGpPWpGaD
Lithium—GSK3B—Senescence and Autophagy in Cancer—IL1A—systemic scleroderma	0.00203	0.00612	CbGpPWpGaD
Lithium—GSK3B—LPA receptor mediated events—MMP2—systemic scleroderma	0.00197	0.00595	CbGpPWpGaD
Lithium—GSK3B—Focal Adhesion—BLK—systemic scleroderma	0.00197	0.00594	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—BLK—systemic scleroderma	0.00193	0.00582	CbGpPWpGaD
Lithium—GSK3A—Leptin signaling pathway—IL1B—systemic scleroderma	0.00187	0.00565	CbGpPWpGaD
Lithium—IMPA2—Metabolism—HSPG2—systemic scleroderma	0.00175	0.00528	CbGpPWpGaD
Lithium—GSK3A—Integrated Breast Cancer Pathway—MMP1—systemic scleroderma	0.00173	0.00523	CbGpPWpGaD
Lithium—GSK3B—Leptin signaling pathway—NOS3—systemic scleroderma	0.00163	0.00491	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—RHOB—systemic scleroderma	0.00162	0.00489	CbGpPWpGaD
Lithium—IMPA1—Metabolism—HSPG2—systemic scleroderma	0.00156	0.00471	CbGpPWpGaD
Lithium—GSK3B—LPA receptor mediated events—MMP9—systemic scleroderma	0.00148	0.00447	CbGpPWpGaD
Lithium—GSK3B—Cardiac Progenitor Differentiation—TGFB1—systemic scleroderma	0.00142	0.00428	CbGpPWpGaD
Lithium—GSK3B—Leptin signaling pathway—IL1B—systemic scleroderma	0.00138	0.00417	CbGpPWpGaD
Lithium—GSK3B—Corticotropin-releasing hormone—NOS3—systemic scleroderma	0.00138	0.00417	CbGpPWpGaD
Lithium—GSK3B—Cardiac Hypertrophic Response—TGFB1—systemic scleroderma	0.00138	0.00416	CbGpPWpGaD
Lithium—GSK3B—Alzheimers Disease—IL1B—systemic scleroderma	0.00133	0.004	CbGpPWpGaD
Lithium—IMPA2—Metabolism—CTGF—systemic scleroderma	0.00133	0.004	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—CSK—systemic scleroderma	0.00121	0.00365	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—CD247—systemic scleroderma	0.00118	0.00357	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—ITGAM—systemic scleroderma	0.00118	0.00357	CbGpPWpGaD
Lithium—IMPA1—Metabolism—CTGF—systemic scleroderma	0.00118	0.00357	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—RHOB—systemic scleroderma	0.00116	0.00349	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—CD247—systemic scleroderma	0.00114	0.00343	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—TNFAIP3—systemic scleroderma	0.00111	0.00335	CbGpPWpGaD
Lithium—GSK3A—Signaling by SCF-KIT—MMP9—systemic scleroderma	0.00106	0.00321	CbGpPWpGaD
Lithium—GSK3B—Senescence and Autophagy in Cancer—IL1B—systemic scleroderma	0.00106	0.00319	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—BLK—systemic scleroderma	0.00105	0.00317	CbGpPWpGaD
Lithium—Angioedema—Leflunomide—systemic scleroderma	0.00103	0.00211	CcSEcCtD
Lithium—Musculoskeletal discomfort—Captopril—systemic scleroderma	0.00102	0.00208	CcSEcCtD
Lithium—Arthralgia—Azathioprine—systemic scleroderma	0.00102	0.00208	CcSEcCtD
Lithium—Vision blurred—Mycophenolic acid—systemic scleroderma	0.00102	0.00208	CcSEcCtD
Lithium—Vertigo—Leflunomide—systemic scleroderma	0.00101	0.00207	CcSEcCtD
Lithium—Diarrhoea—Pentoxifylline—systemic scleroderma	0.00101	0.00206	CcSEcCtD
Lithium—Tremor—Mycophenolic acid—systemic scleroderma	0.00101	0.00206	CcSEcCtD
Lithium—Coma—Methotrexate—systemic scleroderma	0.00101	0.00206	CcSEcCtD
Lithium—Abdominal pain—Mometasone—systemic scleroderma	0.00101	0.00206	CcSEcCtD
Lithium—Body temperature increased—Mometasone—systemic scleroderma	0.00101	0.00206	CcSEcCtD
Lithium—Discomfort—Azathioprine—systemic scleroderma	0.00101	0.00206	CcSEcCtD
Lithium—Urine output increased—Methotrexate—systemic scleroderma	0.000996	0.00204	CcSEcCtD
Lithium—Arrhythmia—Lisinopril—systemic scleroderma	0.000996	0.00204	CcSEcCtD
Lithium—Bradycardia—Mycophenolate mofetil—systemic scleroderma	0.000994	0.00203	CcSEcCtD
Lithium—Somnolence—Captopril—systemic scleroderma	0.000994	0.00203	CcSEcCtD
Lithium—Agitation—Mycophenolic acid—systemic scleroderma	0.00099	0.00202	CcSEcCtD
Lithium—Alopecia—Lisinopril—systemic scleroderma	0.000985	0.00201	CcSEcCtD
Lithium—Dyspepsia—Captopril—systemic scleroderma	0.000984	0.00201	CcSEcCtD
Lithium—GSK3B—MicroRNAs in cardiomyocyte hypertrophy—TGFB1—systemic scleroderma	0.000982	0.00296	CbGpPWpGaD
Lithium—Lethargy—Prednisone—systemic scleroderma	0.000977	0.002	CcSEcCtD
Lithium—Dizziness—Pentoxifylline—systemic scleroderma	0.000976	0.002	CcSEcCtD
Lithium—Decreased appetite—Captopril—systemic scleroderma	0.000972	0.00199	CcSEcCtD
Lithium—Hallucination—Mycophenolate mofetil—systemic scleroderma	0.000972	0.00199	CcSEcCtD
Lithium—GSK3B—Cellular responses to stress—IL1A—systemic scleroderma	0.000969	0.00293	CbGpPWpGaD
Lithium—Vertigo—Mycophenolic acid—systemic scleroderma	0.000968	0.00198	CcSEcCtD
Lithium—Syncope—Mycophenolic acid—systemic scleroderma	0.000966	0.00198	CcSEcCtD
Lithium—Fatigue—Captopril—systemic scleroderma	0.000964	0.00197	CcSEcCtD
Lithium—Arthralgia—Leflunomide—systemic scleroderma	0.000961	0.00197	CcSEcCtD
Lithium—GSK3A—Disease—SMAD7—systemic scleroderma	0.000961	0.0029	CbGpPWpGaD
Lithium—Flatulence—Lisinopril—systemic scleroderma	0.000956	0.00196	CcSEcCtD
Lithium—Dysgeusia—Lisinopril—systemic scleroderma	0.00095	0.00194	CcSEcCtD
Lithium—Discomfort—Leflunomide—systemic scleroderma	0.00095	0.00194	CcSEcCtD
Lithium—Loss of consciousness—Mycophenolic acid—systemic scleroderma	0.000947	0.00194	CcSEcCtD
Lithium—Dry mouth—Leflunomide—systemic scleroderma	0.00094	0.00192	CcSEcCtD
Lithium—Vomiting—Pentoxifylline—systemic scleroderma	0.000938	0.00192	CcSEcCtD
Lithium—Convulsion—Mycophenolic acid—systemic scleroderma	0.000933	0.00191	CcSEcCtD
Lithium—Rash—Pentoxifylline—systemic scleroderma	0.00093	0.0019	CcSEcCtD
Lithium—Dermatitis—Pentoxifylline—systemic scleroderma	0.00093	0.0019	CcSEcCtD
Lithium—Headache—Pentoxifylline—systemic scleroderma	0.000924	0.00189	CcSEcCtD
Lithium—Feeling abnormal—Captopril—systemic scleroderma	0.000922	0.00188	CcSEcCtD
Lithium—Arthralgia—Mycophenolic acid—systemic scleroderma	0.000917	0.00188	CcSEcCtD
Lithium—Vision blurred—Lisinopril—systemic scleroderma	0.000914	0.00187	CcSEcCtD
Lithium—Gastrointestinal pain—Captopril—systemic scleroderma	0.000914	0.00187	CcSEcCtD
Lithium—Asthenia—Mometasone—systemic scleroderma	0.000913	0.00187	CcSEcCtD
Lithium—GSK3B—Corticotropin-releasing hormone—TGFB1—systemic scleroderma	0.000913	0.00276	CbGpPWpGaD
Lithium—Hypotension—Azathioprine—systemic scleroderma	0.000912	0.00186	CcSEcCtD
Lithium—Polyuria—Methotrexate—systemic scleroderma	0.000911	0.00186	CcSEcCtD
Lithium—Tinnitus—Mycophenolate mofetil—systemic scleroderma	0.000911	0.00186	CcSEcCtD
Lithium—Tremor—Lisinopril—systemic scleroderma	0.000909	0.00186	CcSEcCtD
Lithium—Discomfort—Mycophenolic acid—systemic scleroderma	0.000906	0.00185	CcSEcCtD
Lithium—Dry mouth—Mycophenolic acid—systemic scleroderma	0.000897	0.00183	CcSEcCtD
Lithium—GSK3B—Adaptive Immune System—CSK—systemic scleroderma	0.000893	0.0027	CbGpPWpGaD
Lithium—Musculoskeletal discomfort—Azathioprine—systemic scleroderma	0.000889	0.00182	CcSEcCtD
Lithium—Angioedema—Lisinopril—systemic scleroderma	0.000887	0.00181	CcSEcCtD
Lithium—Confusional state—Mycophenolic acid—systemic scleroderma	0.000887	0.00181	CcSEcCtD
Lithium—Abdominal pain—Captopril—systemic scleroderma	0.000884	0.00181	CcSEcCtD
Lithium—Body temperature increased—Captopril—systemic scleroderma	0.000884	0.00181	CcSEcCtD
Lithium—Oedema—Mycophenolic acid—systemic scleroderma	0.000879	0.0018	CcSEcCtD
Lithium—GSK3A—Disease—TGFBI—systemic scleroderma	0.000879	0.00265	CbGpPWpGaD
Lithium—Anorexia—Leflunomide—systemic scleroderma	0.000879	0.0018	CcSEcCtD
Lithium—Dry skin—Prednisone—systemic scleroderma	0.000877	0.00179	CcSEcCtD
Lithium—Nausea—Pentoxifylline—systemic scleroderma	0.000876	0.00179	CcSEcCtD
Lithium—GSK3B—Innate Immune System—ITGAM—systemic scleroderma	0.000875	0.00264	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—CD247—systemic scleroderma	0.000875	0.00264	CbGpPWpGaD
Lithium—Arrhythmia—Mycophenolate mofetil—systemic scleroderma	0.000872	0.00178	CcSEcCtD
Lithium—Vertigo—Lisinopril—systemic scleroderma	0.000872	0.00178	CcSEcCtD
Lithium—Diarrhoea—Mometasone—systemic scleroderma	0.000871	0.00178	CcSEcCtD
Lithium—Syncope—Lisinopril—systemic scleroderma	0.00087	0.00178	CcSEcCtD
Lithium—Shock—Mycophenolic acid—systemic scleroderma	0.000865	0.00177	CcSEcCtD
Lithium—Alopecia—Mycophenolate mofetil—systemic scleroderma	0.000863	0.00176	CcSEcCtD
Lithium—GSK3A—Adaptive Immune System—CTLA4—systemic scleroderma	0.000861	0.0026	CbGpPWpGaD
Lithium—Hypotension—Leflunomide—systemic scleroderma	0.000861	0.00176	CcSEcCtD
Lithium—Loss of consciousness—Lisinopril—systemic scleroderma	0.000853	0.00174	CcSEcCtD
Lithium—Muscular weakness—Prednisone—systemic scleroderma	0.000844	0.00173	CcSEcCtD
Lithium—GSK3B—Cell Cycle—TGFB1—systemic scleroderma	0.00084	0.00254	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—CD247—systemic scleroderma	0.00084	0.00254	CbGpPWpGaD
Lithium—Musculoskeletal discomfort—Leflunomide—systemic scleroderma	0.00084	0.00172	CcSEcCtD
Lithium—Anorexia—Mycophenolic acid—systemic scleroderma	0.000838	0.00171	CcSEcCtD
Lithium—Flatulence—Mycophenolate mofetil—systemic scleroderma	0.000838	0.00171	CcSEcCtD
Lithium—Dysgeusia—Mycophenolate mofetil—systemic scleroderma	0.000833	0.0017	CcSEcCtD
Lithium—Arthralgia—Lisinopril—systemic scleroderma	0.000826	0.00169	CcSEcCtD
Lithium—Hypotension—Mycophenolic acid—systemic scleroderma	0.000822	0.00168	CcSEcCtD
Lithium—GSK3B—Senescence and Autophagy in Cancer—TGFB1—systemic scleroderma	0.000821	0.00248	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—TNFAIP3—systemic scleroderma	0.000819	0.00247	CbGpPWpGaD
Lithium—Discomfort—Lisinopril—systemic scleroderma	0.000816	0.00167	CcSEcCtD
Lithium—Lethargy—Methotrexate—systemic scleroderma	0.000816	0.00167	CcSEcCtD
Lithium—Dyspepsia—Leflunomide—systemic scleroderma	0.000811	0.00166	CcSEcCtD
Lithium—Vomiting—Mometasone—systemic scleroderma	0.00081	0.00166	CcSEcCtD
Lithium—Dry mouth—Lisinopril—systemic scleroderma	0.000808	0.00165	CcSEcCtD
Lithium—GSK3A—Metabolism of proteins—ACE—systemic scleroderma	0.000807	0.00244	CbGpPWpGaD
Lithium—Feeling abnormal—Azathioprine—systemic scleroderma	0.000804	0.00164	CcSEcCtD
Lithium—Rash—Mometasone—systemic scleroderma	0.000803	0.00164	CcSEcCtD
Lithium—Asthenia—Captopril—systemic scleroderma	0.000802	0.00164	CcSEcCtD
Lithium—Dermatitis—Mometasone—systemic scleroderma	0.000802	0.00164	CcSEcCtD
Lithium—Decreased appetite—Leflunomide—systemic scleroderma	0.000801	0.00164	CcSEcCtD
Lithium—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.000801	0.00164	CcSEcCtD
Lithium—Confusional state—Lisinopril—systemic scleroderma	0.000799	0.00163	CcSEcCtD
Lithium—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.000798	0.00163	CcSEcCtD
Lithium—Headache—Mometasone—systemic scleroderma	0.000798	0.00163	CcSEcCtD
Lithium—GSK3B—DNA Damage Response (only ATM dependent)—TGFB1—systemic scleroderma	0.000797	0.00241	CbGpPWpGaD
Lithium—Tremor—Mycophenolate mofetil—systemic scleroderma	0.000797	0.00163	CcSEcCtD
Lithium—Fatigue—Leflunomide—systemic scleroderma	0.000795	0.00162	CcSEcCtD
Lithium—Oedema—Lisinopril—systemic scleroderma	0.000792	0.00162	CcSEcCtD
Lithium—GSK3B—Signaling by SCF-KIT—MMP9—systemic scleroderma	0.000787	0.00238	CbGpPWpGaD
Lithium—Somnolence—Mycophenolic acid—systemic scleroderma	0.000782	0.0016	CcSEcCtD
Lithium—Agitation—Mycophenolate mofetil—systemic scleroderma	0.000781	0.0016	CcSEcCtD
Lithium—Shock—Lisinopril—systemic scleroderma	0.000779	0.00159	CcSEcCtD
Lithium—GSK3B—Adaptive Immune System—BLK—systemic scleroderma	0.000777	0.00235	CbGpPWpGaD
Lithium—Angioedema—Mycophenolate mofetil—systemic scleroderma	0.000777	0.00159	CcSEcCtD
Lithium—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.000774	0.00158	CcSEcCtD
Lithium—Abdominal pain—Azathioprine—systemic scleroderma	0.000772	0.00158	CcSEcCtD
Lithium—Body temperature increased—Azathioprine—systemic scleroderma	0.000772	0.00158	CcSEcCtD
Lithium—Diarrhoea—Captopril—systemic scleroderma	0.000765	0.00156	CcSEcCtD
Lithium—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.000764	0.00156	CcSEcCtD
Lithium—Vertigo—Mycophenolate mofetil—systemic scleroderma	0.000764	0.00156	CcSEcCtD
Lithium—Syncope—Mycophenolate mofetil—systemic scleroderma	0.000762	0.00156	CcSEcCtD
Lithium—Erectile dysfunction—Prednisone—systemic scleroderma	0.000762	0.00156	CcSEcCtD
Lithium—Feeling abnormal—Leflunomide—systemic scleroderma	0.000759	0.00155	CcSEcCtD
Lithium—Fatigue—Mycophenolic acid—systemic scleroderma	0.000758	0.00155	CcSEcCtD
Lithium—Nausea—Mometasone—systemic scleroderma	0.000756	0.00155	CcSEcCtD
Lithium—Anorexia—Lisinopril—systemic scleroderma	0.000755	0.00154	CcSEcCtD
Lithium—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000754	0.00154	CcSEcCtD
Lithium—Weight increased—Prednisone—systemic scleroderma	0.000753	0.00154	CcSEcCtD
Lithium—Ataxia—Methotrexate—systemic scleroderma	0.000752	0.00154	CcSEcCtD
Lithium—Weight decreased—Prednisone—systemic scleroderma	0.000748	0.00153	CcSEcCtD
Lithium—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.000747	0.00153	CcSEcCtD
Lithium—Hyperglycaemia—Prednisone—systemic scleroderma	0.000746	0.00153	CcSEcCtD
Lithium—Hypotension—Lisinopril—systemic scleroderma	0.00074	0.00151	CcSEcCtD
Lithium—Dizziness—Captopril—systemic scleroderma	0.000739	0.00151	CcSEcCtD
Lithium—Convulsion—Mycophenolate mofetil—systemic scleroderma	0.000737	0.00151	CcSEcCtD
Lithium—GSK3A—Immune System—CSK—systemic scleroderma	0.000733	0.00221	CbGpPWpGaD
Lithium—Body temperature increased—Leflunomide—systemic scleroderma	0.000729	0.00149	CcSEcCtD
Lithium—Abdominal pain—Leflunomide—systemic scleroderma	0.000729	0.00149	CcSEcCtD
Lithium—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000725	0.00148	CcSEcCtD
Lithium—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000724	0.00148	CcSEcCtD
Lithium—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000722	0.00148	CcSEcCtD
Lithium—GSK3A—Immune System—IRF5—systemic scleroderma	0.000721	0.00218	CbGpPWpGaD
Lithium—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000719	0.00147	CcSEcCtD
Lithium—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.000715	0.00146	CcSEcCtD
Lithium—Vomiting—Captopril—systemic scleroderma	0.000711	0.00145	CcSEcCtD
Lithium—GSK3B—Disease—SMAD7—systemic scleroderma	0.00071	0.00214	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—HLA-DQB1—systemic scleroderma	0.000709	0.00214	CbGpPWpGaD
Lithium—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000708	0.00145	CcSEcCtD
Lithium—Rash—Captopril—systemic scleroderma	0.000705	0.00144	CcSEcCtD
Lithium—Dermatitis—Captopril—systemic scleroderma	0.000704	0.00144	CcSEcCtD
Lithium—Somnolence—Lisinopril—systemic scleroderma	0.000704	0.00144	CcSEcCtD
Lithium—GSK3A—Disease—HSPG2—systemic scleroderma	0.000701	0.00212	CbGpPWpGaD
Lithium—Headache—Captopril—systemic scleroderma	0.000701	0.00143	CcSEcCtD
Lithium—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.0007	0.00143	CcSEcCtD
Lithium—Dyspepsia—Lisinopril—systemic scleroderma	0.000697	0.00143	CcSEcCtD
Lithium—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000695	0.00142	CcSEcCtD
Lithium—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000695	0.00142	CcSEcCtD
Lithium—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000694	0.00142	CcSEcCtD
Lithium—GSK3A—Immune System—ITGAM—systemic scleroderma	0.000689	0.00208	CbGpPWpGaD
Lithium—GSK3A—Immune System—CD247—systemic scleroderma	0.000689	0.00208	CbGpPWpGaD
Lithium—GSK3A—Immune System—IRF8—systemic scleroderma	0.000689	0.00208	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	0.000688	0.00208	CbGpPWpGaD
Lithium—Decreased appetite—Lisinopril—systemic scleroderma	0.000688	0.00141	CcSEcCtD
Lithium—Fatigue—Lisinopril—systemic scleroderma	0.000683	0.0014	CcSEcCtD
Lithium—Shock—Mycophenolate mofetil—systemic scleroderma	0.000683	0.0014	CcSEcCtD
Lithium—GSK3A—Disease—CSK—systemic scleroderma	0.000677	0.00204	CbGpPWpGaD
Lithium—Bradycardia—Prednisone—systemic scleroderma	0.000674	0.00138	CcSEcCtD
Lithium—GSK3A—Signaling Pathways—SMAD7—systemic scleroderma	0.000673	0.00203	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—CD40LG—systemic scleroderma	0.00067	0.00202	CbGpPWpGaD
Lithium—Diarrhoea—Azathioprine—systemic scleroderma	0.000668	0.00137	CcSEcCtD
Lithium—Nausea—Captopril—systemic scleroderma	0.000664	0.00136	CcSEcCtD
Lithium—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000661	0.00135	CcSEcCtD
Lithium—Asthenia—Leflunomide—systemic scleroderma	0.000661	0.00135	CcSEcCtD
Lithium—Hallucination—Prednisone—systemic scleroderma	0.000659	0.00135	CcSEcCtD
Lithium—Feeling abnormal—Lisinopril—systemic scleroderma	0.000653	0.00133	CcSEcCtD
Lithium—GSK3B—Disease—TGFBI—systemic scleroderma	0.000649	0.00196	CbGpPWpGaD
Lithium—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.000648	0.00133	CcSEcCtD
Lithium—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000648	0.00132	CcSEcCtD
Lithium—GSK3A—Immune System—TNFAIP3—systemic scleroderma	0.000645	0.00195	CbGpPWpGaD
Lithium—Dizziness—Azathioprine—systemic scleroderma	0.000645	0.00132	CcSEcCtD
Lithium—GSK3A—Immune System—BLK—systemic scleroderma	0.000638	0.00193	CbGpPWpGaD
Lithium—Erectile dysfunction—Methotrexate—systemic scleroderma	0.000637	0.0013	CcSEcCtD
Lithium—GSK3B—Adaptive Immune System—CTLA4—systemic scleroderma	0.000636	0.00192	CbGpPWpGaD
Lithium—GSK3A—Disease—CD247—systemic scleroderma	0.000636	0.00192	CbGpPWpGaD
Lithium—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000632	0.00129	CcSEcCtD
Lithium—Asthenia—Mycophenolic acid—systemic scleroderma	0.000631	0.00129	CcSEcCtD
Lithium—Diarrhoea—Leflunomide—systemic scleroderma	0.000631	0.00129	CcSEcCtD
Lithium—Body temperature increased—Lisinopril—systemic scleroderma	0.000626	0.00128	CcSEcCtD
Lithium—Abdominal pain—Lisinopril—systemic scleroderma	0.000626	0.00128	CcSEcCtD
Lithium—Vomiting—Azathioprine—systemic scleroderma	0.000621	0.00127	CcSEcCtD
Lithium—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000617	0.00126	CcSEcCtD
Lithium—Drowsiness—Methotrexate—systemic scleroderma	0.000616	0.00126	CcSEcCtD
Lithium—Rash—Azathioprine—systemic scleroderma	0.000615	0.00126	CcSEcCtD
Lithium—Dermatitis—Azathioprine—systemic scleroderma	0.000615	0.00126	CcSEcCtD
Lithium—Headache—Azathioprine—systemic scleroderma	0.000611	0.00125	CcSEcCtD
Lithium—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000611	0.00125	CcSEcCtD
Lithium—Dizziness—Leflunomide—systemic scleroderma	0.000609	0.00125	CcSEcCtD
Lithium—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000603	0.00123	CcSEcCtD
Lithium—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000602	0.00123	CcSEcCtD
Lithium—Arrhythmia—Prednisone—systemic scleroderma	0.000591	0.00121	CcSEcCtD
Lithium—Vomiting—Leflunomide—systemic scleroderma	0.000586	0.0012	CcSEcCtD
Lithium—Alopecia—Prednisone—systemic scleroderma	0.000585	0.0012	CcSEcCtD
Lithium—Dizziness—Mycophenolic acid—systemic scleroderma	0.000581	0.00119	CcSEcCtD
Lithium—Rash—Leflunomide—systemic scleroderma	0.000581	0.00119	CcSEcCtD
Lithium—Dermatitis—Leflunomide—systemic scleroderma	0.000581	0.00119	CcSEcCtD
Lithium—Nausea—Azathioprine—systemic scleroderma	0.00058	0.00119	CcSEcCtD
Lithium—Headache—Leflunomide—systemic scleroderma	0.000577	0.00118	CcSEcCtD
Lithium—IMPA2—Metabolism—NOS3—systemic scleroderma	0.000577	0.00174	CbGpPWpGaD
Lithium—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000572	0.00117	CcSEcCtD
Lithium—Asthenia—Lisinopril—systemic scleroderma	0.000568	0.00116	CcSEcCtD
Lithium—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000567	0.00116	CcSEcCtD
Lithium—Vomiting—Mycophenolic acid—systemic scleroderma	0.000559	0.00114	CcSEcCtD
Lithium—Rash—Mycophenolic acid—systemic scleroderma	0.000554	0.00113	CcSEcCtD
Lithium—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000554	0.00113	CcSEcCtD
Lithium—Headache—Mycophenolic acid—systemic scleroderma	0.000551	0.00113	CcSEcCtD
Lithium—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000549	0.00112	CcSEcCtD
Lithium—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000549	0.00112	CcSEcCtD
Lithium—Nausea—Leflunomide—systemic scleroderma	0.000547	0.00112	CcSEcCtD
Lithium—Vision blurred—Prednisone—systemic scleroderma	0.000543	0.00111	CcSEcCtD
Lithium—Diarrhoea—Lisinopril—systemic scleroderma	0.000542	0.00111	CcSEcCtD
Lithium—GSK3B—Immune System—CSK—systemic scleroderma	0.000542	0.00164	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—MMP2—systemic scleroderma	0.000538	0.00162	CbGpPWpGaD
Lithium—GSK3B—Immune System—IRF5—systemic scleroderma	0.000533	0.00161	CbGpPWpGaD
Lithium—Agitation—Prednisone—systemic scleroderma	0.00053	0.00108	CcSEcCtD
Lithium—Angioedema—Prednisone—systemic scleroderma	0.000527	0.00108	CcSEcCtD
Lithium—GSK3B—Adaptive Immune System—HLA-DQB1—systemic scleroderma	0.000524	0.00158	CbGpPWpGaD
Lithium—Dizziness—Lisinopril—systemic scleroderma	0.000524	0.00107	CcSEcCtD
Lithium—GSK3A—Immune System—CTLA4—systemic scleroderma	0.000522	0.00158	CbGpPWpGaD
Lithium—Nausea—Mycophenolic acid—systemic scleroderma	0.000522	0.00107	CcSEcCtD
Lithium—GSK3A—Signaling Pathways—RHOB—systemic scleroderma	0.00052	0.00157	CbGpPWpGaD
Lithium—GSK3A—Metabolism of proteins—MMP1—systemic scleroderma	0.000518	0.00156	CbGpPWpGaD
Lithium—GSK3B—Disease—HSPG2—systemic scleroderma	0.000518	0.00156	CbGpPWpGaD
Lithium—Vertigo—Prednisone—systemic scleroderma	0.000518	0.00106	CcSEcCtD
Lithium—Syncope—Prednisone—systemic scleroderma	0.000517	0.00106	CcSEcCtD
Lithium—Tinnitus—Methotrexate—systemic scleroderma	0.000516	0.00105	CcSEcCtD
Lithium—IMPA1—Metabolism—NOS3—systemic scleroderma	0.000514	0.00155	CbGpPWpGaD
Lithium—GSK3B—Immune System—IRF8—systemic scleroderma	0.000509	0.00154	CbGpPWpGaD
Lithium—GSK3B—Immune System—CD247—systemic scleroderma	0.000509	0.00154	CbGpPWpGaD
Lithium—GSK3B—Immune System—ITGAM—systemic scleroderma	0.000509	0.00154	CbGpPWpGaD
Lithium—Loss of consciousness—Prednisone—systemic scleroderma	0.000507	0.00104	CcSEcCtD
Lithium—Vomiting—Lisinopril—systemic scleroderma	0.000504	0.00103	CcSEcCtD
Lithium—GSK3B—Disease—CSK—systemic scleroderma	0.0005	0.00151	CbGpPWpGaD
Lithium—Rash—Lisinopril—systemic scleroderma	0.000499	0.00102	CcSEcCtD
Lithium—Convulsion—Prednisone—systemic scleroderma	0.000499	0.00102	CcSEcCtD
Lithium—Dermatitis—Lisinopril—systemic scleroderma	0.000499	0.00102	CcSEcCtD
Lithium—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000498	0.00102	CcSEcCtD
Lithium—GSK3B—Signaling Pathways—SMAD7—systemic scleroderma	0.000497	0.0015	CbGpPWpGaD
Lithium—Headache—Lisinopril—systemic scleroderma	0.000496	0.00101	CcSEcCtD
Lithium—GSK3B—Adaptive Immune System—CD40LG—systemic scleroderma	0.000495	0.00149	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—HSPG2—systemic scleroderma	0.000491	0.00148	CbGpPWpGaD
Lithium—Arthralgia—Prednisone—systemic scleroderma	0.000491	0.001	CcSEcCtD
Lithium—Alopecia—Methotrexate—systemic scleroderma	0.000489	0.001	CcSEcCtD
Lithium—Discomfort—Prednisone—systemic scleroderma	0.000485	0.000991	CcSEcCtD
Lithium—GSK3B—Immune System—TNFAIP3—systemic scleroderma	0.000477	0.00144	CbGpPWpGaD
Lithium—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000475	0.000971	CcSEcCtD
Lithium—GSK3A—Signaling Pathways—CSK—systemic scleroderma	0.000474	0.00143	CbGpPWpGaD
Lithium—Dysgeusia—Methotrexate—systemic scleroderma	0.000472	0.000964	CcSEcCtD
Lithium—GSK3B—Immune System—BLK—systemic scleroderma	0.000471	0.00142	CbGpPWpGaD
Lithium—Nausea—Lisinopril—systemic scleroderma	0.00047	0.000962	CcSEcCtD
Lithium—Oedema—Prednisone—systemic scleroderma	0.00047	0.000962	CcSEcCtD
Lithium—GSK3B—Disease—CD247—systemic scleroderma	0.00047	0.00142	CbGpPWpGaD
Lithium—Shock—Prednisone—systemic scleroderma	0.000463	0.000946	CcSEcCtD
Lithium—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000459	0.000938	CcSEcCtD
Lithium—Vision blurred—Methotrexate—systemic scleroderma	0.000454	0.000928	CcSEcCtD
Lithium—Anorexia—Prednisone—systemic scleroderma	0.000448	0.000917	CcSEcCtD
Lithium—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000441	0.000902	CcSEcCtD
Lithium—Rash—Mycophenolate mofetil—systemic scleroderma	0.000438	0.000895	CcSEcCtD
Lithium—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000437	0.000894	CcSEcCtD
Lithium—Headache—Mycophenolate mofetil—systemic scleroderma	0.000435	0.000889	CcSEcCtD
Lithium—Vertigo—Methotrexate—systemic scleroderma	0.000433	0.000885	CcSEcCtD
Lithium—GSK3A—Immune System—HLA-DQB1—systemic scleroderma	0.00043	0.0013	CbGpPWpGaD
Lithium—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000429	0.000876	CcSEcCtD
Lithium—GSK3A—Metabolism of proteins—CCL2—systemic scleroderma	0.000421	0.00127	CbGpPWpGaD
Lithium—Convulsion—Methotrexate—systemic scleroderma	0.000417	0.000853	CcSEcCtD
Lithium—Dyspepsia—Prednisone—systemic scleroderma	0.000414	0.000847	CcSEcCtD
Lithium—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000412	0.000843	CcSEcCtD
Lithium—Arthralgia—Methotrexate—systemic scleroderma	0.00041	0.000838	CcSEcCtD
Lithium—Decreased appetite—Prednisone—systemic scleroderma	0.000409	0.000836	CcSEcCtD
Lithium—GSK3A—Immune System—IL1A—systemic scleroderma	0.000409	0.00123	CbGpPWpGaD
Lithium—GSK3A—Immune System—CD40LG—systemic scleroderma	0.000406	0.00123	CbGpPWpGaD
Lithium—Fatigue—Prednisone—systemic scleroderma	0.000406	0.000829	CcSEcCtD
Lithium—Discomfort—Methotrexate—systemic scleroderma	0.000405	0.000828	CcSEcCtD
Lithium—GSK3B—Axon guidance—MMP9—systemic scleroderma	0.000404	0.00122	CbGpPWpGaD
Lithium—GSK3A—Metabolism of proteins—MMP2—systemic scleroderma	0.000401	0.00121	CbGpPWpGaD
Lithium—Confusional state—Methotrexate—systemic scleroderma	0.000396	0.00081	CcSEcCtD
Lithium—Feeling abnormal—Prednisone—systemic scleroderma	0.000388	0.000793	CcSEcCtD
Lithium—GSK3B—Immune System—CTLA4—systemic scleroderma	0.000386	0.00117	CbGpPWpGaD
Lithium—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000385	0.000786	CcSEcCtD
Lithium—GSK3B—Signaling Pathways—RHOB—systemic scleroderma	0.000385	0.00116	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—MMP2—systemic scleroderma	0.000384	0.00116	CbGpPWpGaD
Lithium—Anorexia—Methotrexate—systemic scleroderma	0.000375	0.000766	CcSEcCtD
Lithium—Abdominal pain—Prednisone—systemic scleroderma	0.000372	0.00076	CcSEcCtD
Lithium—Body temperature increased—Prednisone—systemic scleroderma	0.000372	0.00076	CcSEcCtD
Lithium—Hypotension—Methotrexate—systemic scleroderma	0.000367	0.000751	CcSEcCtD
Lithium—GSK3B—Signaling Pathways—HSPG2—systemic scleroderma	0.000363	0.00109	CbGpPWpGaD
Lithium—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.000358	0.000732	CcSEcCtD
Lithium—GSK3B—Signaling Pathways—CSK—systemic scleroderma	0.00035	0.00106	CbGpPWpGaD
Lithium—Somnolence—Methotrexate—systemic scleroderma	0.000349	0.000715	CcSEcCtD
Lithium—Dyspepsia—Methotrexate—systemic scleroderma	0.000346	0.000708	CcSEcCtD
Lithium—Decreased appetite—Methotrexate—systemic scleroderma	0.000342	0.000699	CcSEcCtD
Lithium—Fatigue—Methotrexate—systemic scleroderma	0.000339	0.000693	CcSEcCtD
Lithium—Asthenia—Prednisone—systemic scleroderma	0.000337	0.00069	CcSEcCtD
Lithium—Feeling abnormal—Methotrexate—systemic scleroderma	0.000324	0.000662	CcSEcCtD
Lithium—Diarrhoea—Prednisone—systemic scleroderma	0.000322	0.000658	CcSEcCtD
Lithium—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000321	0.000657	CcSEcCtD
Lithium—GSK3B—Immune System—HLA-DQB1—systemic scleroderma	0.000318	0.00096	CbGpPWpGaD
Lithium—Dizziness—Prednisone—systemic scleroderma	0.000311	0.000636	CcSEcCtD
Lithium—Abdominal pain—Methotrexate—systemic scleroderma	0.000311	0.000635	CcSEcCtD
Lithium—Body temperature increased—Methotrexate—systemic scleroderma	0.000311	0.000635	CcSEcCtD
Lithium—GSK3B—Immune System—IL1A—systemic scleroderma	0.000302	0.000912	CbGpPWpGaD
Lithium—GSK3B—Immune System—CD40LG—systemic scleroderma	0.0003	0.000906	CbGpPWpGaD
Lithium—Vomiting—Prednisone—systemic scleroderma	0.000299	0.000611	CcSEcCtD
Lithium—Rash—Prednisone—systemic scleroderma	0.000297	0.000606	CcSEcCtD
Lithium—Dermatitis—Prednisone—systemic scleroderma	0.000296	0.000606	CcSEcCtD
Lithium—Headache—Prednisone—systemic scleroderma	0.000295	0.000602	CcSEcCtD
Lithium—GSK3B—Developmental Biology—MMP9—systemic scleroderma	0.000289	0.000871	CbGpPWpGaD
Lithium—Asthenia—Methotrexate—systemic scleroderma	0.000282	0.000577	CcSEcCtD
Lithium—Nausea—Prednisone—systemic scleroderma	0.000279	0.000571	CcSEcCtD
Lithium—Diarrhoea—Methotrexate—systemic scleroderma	0.000269	0.00055	CcSEcCtD
Lithium—GSK3A—Signaling Pathways—EDN1—systemic scleroderma	0.000266	0.000802	CbGpPWpGaD
Lithium—Dizziness—Methotrexate—systemic scleroderma	0.00026	0.000532	CcSEcCtD
Lithium—Vomiting—Methotrexate—systemic scleroderma	0.00025	0.000511	CcSEcCtD
Lithium—Rash—Methotrexate—systemic scleroderma	0.000248	0.000507	CcSEcCtD
Lithium—Dermatitis—Methotrexate—systemic scleroderma	0.000248	0.000506	CcSEcCtD
Lithium—Headache—Methotrexate—systemic scleroderma	0.000246	0.000504	CcSEcCtD
Lithium—GSK3B—Developmental Biology—TGFB1—systemic scleroderma	0.000238	0.000718	CbGpPWpGaD
Lithium—Nausea—Methotrexate—systemic scleroderma	0.000233	0.000477	CcSEcCtD
Lithium—GSK3A—Disease—NOS3—systemic scleroderma	0.000231	0.000698	CbGpPWpGaD
Lithium—GSK3A—Immune System—IL1B—systemic scleroderma	0.000213	0.000643	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—EDN1—systemic scleroderma	0.000196	0.000593	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CCL2—systemic scleroderma	0.000182	0.000548	CbGpPWpGaD
Lithium—GSK3B—Disease—NOS3—systemic scleroderma	0.000171	0.000516	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—NOS3—systemic scleroderma	0.000162	0.000489	CbGpPWpGaD
Lithium—GSK3B—Immune System—IL1B—systemic scleroderma	0.000157	0.000475	CbGpPWpGaD
Lithium—GSK3A—Disease—TGFB1—systemic scleroderma	0.000153	0.000462	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CCL2—systemic scleroderma	0.000134	0.000405	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—MMP9—systemic scleroderma	0.00013	0.000392	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—NOS3—systemic scleroderma	0.00012	0.000361	CbGpPWpGaD
Lithium—GSK3B—Disease—TGFB1—systemic scleroderma	0.000113	0.000341	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TGFB1—systemic scleroderma	0.000107	0.000323	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MMP9—systemic scleroderma	9.6e-05	0.00029	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TGFB1—systemic scleroderma	7.91e-05	0.000239	CbGpPWpGaD
